These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys. Chen X; Wang J; Fu B; Yu L Biochem Biophys Res Commun; 1997 May; 234(3):594-9. PubMed ID: 9175758 [TBL] [Abstract][Full Text] [Related]
10. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Amin M; Badiee A; Jaafari MR Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663 [TBL] [Abstract][Full Text] [Related]
11. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835 [TBL] [Abstract][Full Text] [Related]
12. Modulation of vitronectin receptor-mediated osteoclast adhesion by Arg-Gly-Asp peptide analogs: a structure-function analysis. Horton MA; Dorey EL; Nesbitt SA; Samanen J; Ali FE; Stadel JM; Nichols A; Greig R; Helfrich MH J Bone Miner Res; 1993 Feb; 8(2):239-47. PubMed ID: 7680185 [TBL] [Abstract][Full Text] [Related]
13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Chavakis E; Riecke B; Lin J; Linn T; Bretzel RG; Preissner KT; Brownlee M; Hammes HP Diabetologia; 2002 Feb; 45(2):262-7. PubMed ID: 11935158 [TBL] [Abstract][Full Text] [Related]
16. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. Dechantsreiter MA; Planker E; Mathä B; Lohof E; Hölzemann G; Jonczyk A; Goodman SL; Kessler H J Med Chem; 1999 Aug; 42(16):3033-40. PubMed ID: 10447947 [TBL] [Abstract][Full Text] [Related]
17. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo. Hall H; Djonov V; Ehrbar M; Hoechli M; Hubbell JA Angiogenesis; 2004; 7(3):213-23. PubMed ID: 15609076 [TBL] [Abstract][Full Text] [Related]
18. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide. Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792 [TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Chatterjee S; Brite KH; Matsumura A Clin Cancer Res; 2001 Oct; 7(10):3006-11. PubMed ID: 11595688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]